title: Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor.
abstract: Corticotropin releasing factor (CRF) is an important regulator of the endocrine, behavioral, autonomic and immune responses to stress. Two high affinity CRF receptors have been identified, which are distributed in distinct anatomical regions. CRF(1) receptors have been relatively well characterized and antagonists to this receptor effectively block stress-induced behaviors in rodents. The function of CRF(2) receptors, which are highly expressed in limbic brain regions, is less well understood. Therefore, an antisense oligonucleotide approach was used to study the role of CRF(2) receptors in the lateral septum in rats. An antisense oligonucleotide directed against the CRF(2) receptor mRNA reduced expression of CRF(2) receptors by 60--80%. In shock-induced freezing tests, animals administered the antisense oligonucleotide exhibited a significant reduction in freezing duration. However, pain sensitivity and locomotor activity were unaltered. A four-base mismatch of the antisense sequence had no significant effects on CRF(2) receptor density and on freezing behavior. These data support the involvement of CRF(2) receptors in fear conditioning. CRF(1) receptor antagonists also reduce freezing in this test. Additional studies to determine the effects of simultaneous inhibition of both receptor subtypes show that rats receiving both CRF(2) receptor antisense oligonucleotide and CRF(1) receptor antagonist froze significantly less than animals treated with either agent alone. These results provide additional evidence for the role of CRF(2) receptors in mediating the stress-induced actions of endogenous CRF.
authors: CNS Diseases Research, DuPont Pharmaceuticals, Experimental Station E400, Wilmington, DE 19880-0400, USA. siew.p.ho@dupontpharma.com
authors: S P
authors: SP
authors: Ho
authors: L K
authors: LK
authors: Takahashi
authors: V
authors: V
authors: Livanov
authors: K
authors: K
authors: Spencer
authors: T
authors: T
authors: Lesher
authors: C
authors: C
authors: Maciag
authors: M A
authors: MA
authors: Smith
authors: K W
authors: KW
authors: Rohrbach
authors: P R
authors: PR
authors: Hartig
authors: S P
authors: SP
authors: Arneric
mesh_terms: D000818:Animals; D016466:CHO Cells; D003213:Conditioning, Psychological / Q000502:physiology*; D006224:Cricetinae; D004597:Electroshock; D005239:Fear / Q000502:physiology*; D007276:Injections, Intraventricular; D008297:Male; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D017288:Pain Threshold / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors* / Q000235:genetics* / Q000378:metabolism; D013216:Reflex, Startle / Q000502:physiology; D012686:Septal Nuclei / Q000502:physiology; D013312:Stress, Physiological / Q000503:physiopathology; D000099052:CRF Receptor, Type 1
chemical_list: C101531:CRF receptor type 2; D016376:Oligonucleotides, Antisense; D018019:Receptors, Corticotropin-Releasing Hormone; D000099052:CRF Receptor, Type 1